NR1H3 and myeloid sarcoma: Clinical information for variant carriers is limited, but suggest that NCOA3 p.Arg485Cys patients developed MS on average at 27.8 years of age (SD ± 5.6), predominantly with a progressive disease course, similar to patients with NR1H3 mutations [9].